Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Bookman

Showing results (11-20 of 74) with videos related to

Pageof 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
The addition of new drugs to standard therapy in the first-line treatment of ovarian cancerM A Bookman
Current Opinion in Oncology|October 1, 1990
Immunotherapy for ovarian cancerM A Bookman
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2016
Optimal primary therapy of ovarian cancerM A Bookman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 21, 2005
Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinicM A Bookman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 14, 2005
Is there still a role for hormonal therapy?M A Bookman
Gynecologic Oncology|October 1, 1993
Biologic therapy in the management of refractory ovarian cancerM A Bookman
The Oncologist|May 25, 1999
Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapyM A Bookman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 8, 2001
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology GroupM A Bookman
The Oncologist|March 8, 2000
Second-line treatment of ovarian cancerM Markman, M A Bookman
The Journal of Clinical Investigation|May 1, 1977
Isolation and functional characterization of human intestinal mucosal lymphoid cellsD M Bull, M A Bookman
Pageof 8

Showing results (11-20 of 74) with videos related to

Sort By:
Pageof 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 15, 2010
The addition of new drugs to standard therapy in the first-line treatment of ovarian cancerM A Bookman
Current Opinion in Oncology|October 1, 1990
Immunotherapy for ovarian cancerM A Bookman
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2016
Optimal primary therapy of ovarian cancerM A Bookman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|April 21, 2005
Gemcitabine monotherapy in recurrent ovarian cancer: from the bench to the clinicM A Bookman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 14, 2005
Is there still a role for hormonal therapy?M A Bookman
Gynecologic Oncology|October 1, 1993
Biologic therapy in the management of refractory ovarian cancerM A Bookman
The Oncologist|May 25, 1999
Extending the platinum-free interval in recurrent ovarian cancer: the role of topotecan in second-line chemotherapyM A Bookman
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|August 8, 2001
Developmental chemotherapy in advanced ovarian cancer: incorporation of topoisomerase-I inhibitors and perspective of the Gynecologic Oncology GroupM A Bookman
The Oncologist|March 8, 2000
Second-line treatment of ovarian cancerM Markman, M A Bookman
The Journal of Clinical Investigation|May 1, 1977
Isolation and functional characterization of human intestinal mucosal lymphoid cellsD M Bull, M A Bookman
Pageof 8